Detecting antibodies that confer effective immunity is crucially important to understand a patient’s immune response to SARS-CoV-2. In particular, the ability to quantify the virus-neutralizing capacity of the immune system is key to support the development of suitable vaccines and antibody-based treatments such as convalescent plasma therapies.
This talk outlines our efforts in assessing the immune response in COVID-19 patients by use of a novel microfluidic in-solution immunoassay platform. With this new approach, we were able to comprehensively profile SARS-CoV-2 antibodies directly in minimally diluted serum of these patients.
During the event, Prof. Tuomas Knowles, Founder and Chief Scientific Officer at Fluidic Analytics, will be looking into:
Certificate of attendance
All webinar participants can request a certificate of attendance, and a learning outcomes summary document for continuing education purposes.
This webinar will run on Friday, September 25, at:
SelectScience runs more than 10 webinars a month across various scientific topics, discover more of our upcoming webinars>>